Neural Analytics, Inc. announced on 5/30/18 that it received FDA 510(k) clearance for its NeuralBot System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. When used with its previously cleared Lucid M1 Transcranial Doppler Ultrasound System, can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders.

Recently, Neural Analytics presented research data that demonstrated there was no statistical difference between ultrasound blood flow data collected with its NeuralBot System or data collected manually by an expert technician with its traditional ultrasound platform.

“Progress in treating neurological disorders has lagged due to a lack of available low-cost and objective patient diagnostic information. This has resulted in misdiagnosis, treatment delays and additional healthcare expenditures for patients suffering neurological disease,” said Robert Hamilton, Ph.D., Co-Founder and Chief Scientific Officer of Neural Analytics. “Our new technology can assist a healthcare professional- when an expert technician is not available - with the collection of blood flow data to assist clinicians in efficiently triaging patients for appropriate treatment.”

Neural Analytics will immediately commercialize the NeuralBot System with its currently available Lucid M1 TCD System in the U.S. as the ‘Lucid Robotic System. The Lucid Robotic System, when used for a transcranial doppler ultrasound procedure for patients suspected of neurological disorder, is reimbursable by Medicare/Medicaid and most private payers.